NCT05361707Phase 3Unknown
Evaluating the Effects of Tasimelteon in Individuals With Autism Spectrum Disorder (ASD) and Sleep Disturbances
Study sponsor: Vanda Pharmaceuticals
Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.
Primary completion2025-07Estimated
Enrollment · participants100Estimated
Source updated2024-03-21Last update listed in the registry record
Version history
Changes to this trial
Pro unlocks the full available history and CSV export. View Pro features
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.